Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA ...

“Data from this large study, including the extensive set of biomarkers collected, will further advance our understanding of the disease and inform our broader NASH development programmes.

The most obvious way that a pair of blood-related parents might increase health risks for a child is through a recessive ...

I'll be the first to attest to the tremendous amount of work required for any successful launch, let alone a first in disease therapy ... enrollment in our MAESTRO-NASH outcomes trial.

The most obvious way that a pair of blood-related parents might increase health risks for a child is through a recessive disorder, like cystic fibrosis or sickle cell disease. According to the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The esteemed actor suffered a hip injury while working on an untitled film that also stars Tom Cruise, Jesse Clemons and Liz ...

One recent morning, curiosity led me to a video promoting Mr. Kennedy’s Make America Healthy Again movement. With the ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...